CITATION REPORT List of articles citing

Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience

DOI: 10.1053/sonc.2001.26151 Seminars in Oncology, 2001, 28, 400-418.

Source: https://exaly.com/paper-pdf/84979215/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 336 | Breast-conserving therapy for ductal carcinoma in situ: a 20-year experience with excision plus radiation therapy. 2002 , 184, 403-9 | | 25 |
| 335 | Duktales Carcinoma in situ (DCIS). 2002, 8, 832-836 | | |
| 334 | Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. 2002 , 53, 868-79 | | 101 |
| 333 | Tamoxifenan update on current data and where it can now be used. <i>Breast Cancer Research and Treatment</i> , 2002 , 75 Suppl 1, S7-12; discussion S33-5 | 4.4 | 25 |
| 332 | The role of aromatase inhibitors in early breast cancer. 2003 , 4, 133-40 | | 12 |
| 331 | Current management of ductal carcinoma in situ of the breast. 2003 , 8, 18-22 | | 15 |
| 330 | Optimal management of ductal carcinoma in situ of the breast. 2003 , 12, 221-40 | | 42 |
| 329 | Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. <i>Breast</i> , 2003 , 12, 457-71 | 3.6 | 57 |
| 328 | Current controversies in ductal carcinoma in situ of the breast: summary from the Lynn Sage Breast Cancer Symposium. 2003 , 197, 115-8 | | 8 |
| 327 | Role of anastrozole in adjuvant therapy for postmenopausal patients. <i>Seminars in Oncology</i> , 2003 , 30, 21-9 | 5.5 | 4 |
| 326 | Treatment of DCISresults from clinical trials. 2003 , 12, 213-9 | | 24 |
| 325 | Hormonal therapy of breast cancer. 2003 , 27, 279-331 | | 2 |
| 324 | Bilateral synchronous breast cancer: a population-based study of characteristics, method of detection, and survival. 2003 , 133, 383-9 | | 35 |
| 323 | Towards optimal management of ductal carcinoma in situ of the breast. <i>European Journal of Surgical Oncology</i> , 2003 , 29, 191-7 | 3.6 | 38 |
| 322 | The diagnosis and management of pre-invasive breast disease: problems associated with management of pre-invasive lesions. 2003 , 5, 309-12 | | 8 |
| 321 | NSABP breast cancer clinical trials: recent results and future directions. 2003 , 1, 309-26 | | 35 |
| 320 | Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. 2003 , 10, 347-57 | | 17 |

| 319 | Ductal carcinoma in situ, complexities and challenges. 2004 , 96, 906-20 | | 291 |
|-----|--|-----|-----|
| 318 | Trends in the treatment of ductal carcinoma in situ of the breast. 2004 , 96, 443-8 | | 281 |
| 317 | Mammographic density and breast cancer after ductal carcinoma in situ. 2004 , 96, 1467-72 | | 57 |
| 316 | Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. 2004 , 15, 1738-47 | | 17 |
| 315 | Chemoprevention of cancer. 2004 , 54, 150-80 | | 212 |
| 314 | Effects of drug treatment for malignancy on skeletal health of cancer survivors. 2004 , 2, 103-114 | | |
| 313 | The role of clinical trials in changing therapy for ductal carcinoma in situ. <i>Annals of Surgical Oncology</i> , 2004 , 11, 24S-27S | 3.1 | 2 |
| 312 | Ductal carcinoma in situ of the breast. Increasing importance of radiotherapy as a part of the therapy approach. 2004 , 180, 682-9 | | 8 |
| 311 | Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. 2004 , 100, 942-9 | | 44 |
| 310 | The management of ductal carcinoma in situ in North America and Europe. Results of a survey. 2004 , 101, 1958-67 | | 44 |
| 309 | Consquences de la sous-estimation du bilan dextension du CCIS : le point de vue du chirurgien. 2004 , 14, 193-196 | | |
| 308 | Ductal carcinoma in situ of the breast. 2004 , 350, 1430-41 | | 433 |
| 307 | Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?. 2004, 30, 325-32 | | 112 |
| 306 | [Ductal in situ carcinoma: is it ethical to consider the breast conserving therapy as a standard?]. 2004 , 8, 9-20 | | 2 |
| 305 | [Ductal carcinoma in situ of the breast. Analysis of 882 cases]. 2004, 33, 83-9 | | 11 |
| 304 | Ductal carcinoma in situ of the breast han overview of the randomized clinical trials. 2004, 7, | | |
| 303 | Prognostic and predictive molecular markers in DCIS: a review. 2005 , 12, 256-64 | | 58 |
| 302 | Premalignant and in situ breast disease: biology and clinical implications. 2005 , 143, 446-57 | | 138 |

| 301 | Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. 2005 , 61, 1054-61 | | 32 |
|--------------------------|--|-----|----------------------|
| 300 | Reduction of radiotherapy-induced late complications in early breast cancer: the role of intensity-modulated radiation therapy and partial breast irradiation. Part Inormal tissue complications. 2005 , 17, 16-24 | | 28 |
| 299 | Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours. <i>Breast</i> , 2005 , 14, 290-7 | 3.6 | 9 |
| 298 | Biological variables and prognosis of DCIS. <i>Breast</i> , 2005 , 14, 509-19 | 3.6 | 20 |
| 297 | Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. 2005 , 116, 820-3 | | 22 |
| 296 | Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. 2005 , 103, 1137-46 | | 149 |
| 295 | Surgeon perspectives about local therapy for breast carcinoma. 2005 , 104, 1854-61 | | 43 |
| 294 | The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. 2005 , 104, 1840-8 | | 55 |
| 293 | Pathology of In Situ Breast Cancer. 2005 , 85-97 | | |
| | | | |
| 292 | Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. 2005 , 97, 1652-62 | | 998 |
| 292 291 | | | 998 |
| | Assessing the benefit of radiation therapy after breast-conserving surgery for ductal | | |
| 291 | Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. 2005 , 23, 5171-7 | | |
| 291 290 | Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. 2005, 23, 5171-7 Carcinome canalaire in situ du sein. Analyse de 882 cas. 2005, 15, 7-14 | | 21 |
| 291 290 289 | Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. 2005, 23, 5171-7 Carcinome canalaire in situ du sein. Analyse de 882 cas. 2005, 15, 7-14 Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?. 2005, 31, 1-17 Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ?. | | 21 |
| 291 290 289 288 | Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. 2005, 23, 5171-7 Carcinome canalaire in situ du sein. Analyse de 882 cas. 2005, 15, 7-14 Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?. 2005, 31, 1-17 Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ?. 2005, 41, 380-5 Salvage treatment for local or local-regional recurrence after initial breast conservation treatment | | 21 22 27 |
| 291 290 289 288 | Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. 2005, 23, 5171-7 Carcinome canalaire in situ du sein. Analyse de 882 cas. 2005, 15, 7-14 Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?. 2005, 31, 1-17 Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ?. 2005, 41, 380-5 Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. 2005, 41, 1715-23 | | 21 22 27 28 |

(2006-2005)

| 283 | of breast cancer. 2005 , 37, 125-30 | 27 |
|-----|--|------|
| 282 | Breast Cancer and Molecular Medicine. 2006 , | 2 |
| 281 | Heterogeneity of ductal carcinoma in situ and its effects on management. 2006, 7, 756-65 | 56 |
| 280 | Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. 2006 , 192, 416-9 | 54 |
| 279 | Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. 2006 , 192, 420-2 | 66 |
| 278 | The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. 2006 , 42, 2205-11 | 75 |
| 277 | Changes in the management of ductal carcinoma in situ before the release of clinical practice recommendations in Australia: the case in Victoria. 2006 , 76, 28-34 | 5 |
| 276 | Radiotherapy for ductal carcinoma in situ. 2006 , 18, 179-84 | 5 |
| 275 | Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. 2006 , 65, 1397-403 | 54 |
| 274 | The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project. 2006 , 30, 1138-46 | 11 |
| 273 | Tamoxifen in ductal carcinoma in situ. <i>Seminars in Oncology</i> , 2006 , 33, 647-9 | 14 |
| 272 | Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. 2006 , 106, 2104-12 | 142 |
| 271 | Quality of life for women diagnosed with breast carcinoma in situ. 2006 , 24, 4875-81 | 15 |
| 270 | Le carcinome canalaire in situ (CCIS) en 2005. 2006 , 131-165 | |
| 269 | Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. 2006 , 295, 2727-41 | 1241 |
| 268 | Effectiveness of radiation therapy in older women with ductal carcinoma in situ. 2006 , 98, 1302-10 | 69 |
| 267 | The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers. 2006 , 24, 361-9 | 71 |
| 266 | Prospective study of wide excision alone for ductal carcinoma in situ of the breast. 2006 , 24, 1031-6 | 209 |

| 265 | Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. | 526 |
|-----|---|-----|
| 264 | 2006 , 24, 3381-7 Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. 2007 , 25, 3251-8 | 40 |
| 263 | Information exchange and decision making in the treatment of Latina and white women with ductal carcinoma in situ. 2007 , 25, 19-36 | 31 |
| 262 | Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. 2007 , 128, 86-91 | 60 |
| 261 | Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. 2007 , 18, 1133-44 | 695 |
| 260 | Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. 2007 , 12, 1276-87 | 51 |
| 259 | Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. 2007 , 25, 5591-6 | 44 |
| 258 | Cancer Chemoprevention. 2007, | |
| 257 | Ductal carcinoma in situ: a review of recent advances. 2007 , 19, 63-7 | 13 |
| 256 | Surgical management of breast cancer. 2007 , 23, 10-9 | 13 |
| 255 | The weakest link. 2007 , 43, 228-30 | |
| 254 | [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy]. 2007 , 35, 1215-9 | 4 |
| 253 | Analyses d'articles. 2007 , 11, 158-166 | |
| 252 | [Bilateral ductal carcinoma in situ of the breast: independent events or bilateral disease?]. 2007, 36, 260-6 | 1 |
| 251 | An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer. 2007 , 84, 11-7 | 19 |
| 250 | Evidence based radiation oncology: breast cancer. 2007 , 84, 84-101 | 74 |
| 249 | Cancer canalaire in situ (CCIS). 2007 , 251-272 | |
| 248 | Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Surgical Clinics of North America, 2007 , 87, 279-305, vii | 10 |

| 247 | Ductal carcinoma in situcurrent management. Surgical Clinics of North America, 2007, 87, 333-51, viii | 1 | 19 |
|-----|--|-----|----|
| 246 | The Current Paradigm for Breast Irradiation: The Case for Treating the Whole Breast over Six Weeks. 2007 , 10, 5-8 | | |
| 245 | Ductal Carcinoma In Situ: Biology, Diagnosis, and New Therapies. 2007 , 7, 16-21 | | 14 |
| 244 | Breast Cancer in Older Patients. 2007 , 2, 386-390 | | 1 |
| 243 | Local Therapy of Early Breast Cancer*. 2007 , 2, 143-148 | | 3 |
| 242 | An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. 2007 , 110, 2648-53 | | 67 |
| 241 | Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? No. One size does not fit all: an argument against the routine use of radiation therapy for all patients with ductal carcinoma in situ of the breast who elect breast conservation. 2007 , 95, 605-9 | | 18 |
| 240 | Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. 2007 , 95, 610-3 | | 12 |
| 239 | National Breast Cancer Audit: ductal carcinoma in situ management in Australia and New Zealand. 2007 , 77, 64-8 | | 14 |
| 238 | The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis. 2007 , 13, 359-67 | | 23 |
| 237 | The dilemma of DCIS. <i>Breast</i> , 2007 , 16 Suppl 2, S59-62 | 3.6 | 9 |
| 236 | Practice guideline for the management of ductal carcinoma in-situ of the breast (DCIS). 2007 , 205, 145-16 | 51 | 24 |
| 235 | Results of 23,810 cases of ductal carcinoma-in-situ. <i>Annals of Surgical Oncology</i> , 2007 , 14, 1638-43 | 3.1 | 48 |
| 234 | Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2008, 111, 531-40 | 1.4 | 36 |
| 233 | The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast. Pathology and Oncology Research, 2008, 14, 179-92 | 2.6 | 6 |
| 232 | The effect of margins on the clinical management of ductal carcinoma in situ of the breast. 2008 , 98, 579-84 | | 13 |
| 231 | Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis. 2008, 72, 1031-40 | | 89 |
| 230 | Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. <i>Annals of Surgical Oncology</i> , 2008 , 15, 235-43 | 3.1 | 68 |

| 229 | Development of new cancers in patients with DCIS: the M.D. Anderson experience. <i>Annals of Surgical Oncology</i> , 2008 , 15, 244-9 | 3.1 | 12 |
|-----|---|-----|-----|
| 228 | Ductal carcinoma in situ: through a glass, darkly. <i>Annals of Surgical Oncology</i> , 2008 , 15, 16-7 | 3.1 | 8 |
| 227 | Breast conservation for ductal carcinoma in situ: Results at an Australian institution with evidence to recommend prospective assessment of the utility of a lumpectomy boost. 2008 , 4, 137-142 | | 1 |
| 226 | Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. 2008 , 14, 33-8 | | 17 |
| 225 | Feasibility of accelerated whole-breast radiation in the treatment of patients with ductal carcinoma in situ of the breast. 2008 , 8, 269-74 | | 18 |
| 224 | Cost-effectiveness of breast cancer screening in women on dialysis. 2008 , 52, 916-29 | | 19 |
| 223 | The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. <i>Seminars in Oncology</i> , 2008 , 35, 522-9 | 5.5 | 11 |
| 222 | The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. 2008 , 6, 61 | | 44 |
| 221 | Multidisciplinary management of ductal carcinoma in situ: a 10-year experience. 2008, 19, 171-172 | | |
| 220 | Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ. 2008 , 196, 552-5 | 5 | 12 |
| 219 | [Ductal carcinoma in situ: role of the boost]. 2008, 12, 571-6 | | 12 |
| 218 | [Ductal carcinoma in situ of the breast (DCIS) under 40: a specific management?]. 2008, 36, 499-506 | | 1 |
| 217 | Prospective Assessment of Radiotherapy-associated Cardiac Toxicity in Breast Cancer Patients: Analysis of Data 3 to 6 Years After Treatment. 2008 , 19, 172-173 | | |
| 216 | Breast disease: benign and malignant. 2008 , 92, 1115-41, x | | 15 |
| 215 | Osteoporosis Associated with Cancer Therapy. 2008 , 1337-1374 | | |
| 214 | Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. 2009 , 27, 5319-24 | | 285 |
| 213 | Clinical dilemma of ductal carcinoma in situ. 2009 , 27, 5303-5 | | 9 |
| 212 | Ductal carcinoma in situ of the breast in Israeli women treated by breast-conserving surgery followed by radiation therapy. 2009 , 76, 30-5 | | 3 |

(2010-2009)

| 211 | Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. 2009 , 33, 1802-8 | | 21 |
|-----|--|-----|-----|
| 210 | Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. 2009 , 14, 201-12 | | 18 |
| 209 | Management Options in Breast Cancer. 2009, | | 2 |
| 208 | The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. 2009 , 18, 1763-9 | | 67 |
| 207 | Post-operative radiotherapy for ductal carcinoma in situ of the breasta systematic review of the randomised trials. <i>Breast</i> , 2009 , 18, 143-9 | 3.6 | 42 |
| 206 | Actual management of ductal carcinoma in situ of the breast. 2009 , 280, 699-705 | | 6 |
| 205 | Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage. 2009 , 75, 1021-8 | | 28 |
| 204 | Ductal carcinoma in situ of the breast. 2009 , 3, 237-246 | | 4 |
| 203 | Systemtherapie des Mammakarzinoms. 2009 , 2, 171-184 | | |
| 202 | St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy. 2009 , 2, 229-231 | | 3 |
| 201 | Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. 2009 , 100, 1048-54 | | 42 |
| 200 | Therapeutic decisions for ductal carcinoma in situ: a Gordian knot. 2009 , 15, 117-9 | | 1 |
| 199 | Outcomes after breast conservation treatment with radiation in women with ductal carcinoma in situ and prior nonbreast malignancy. 2009 , 15, 649-52 | | 1 |
| 198 | Surgical guidelines for the management of breast cancer. <i>European Journal of Surgical Oncology</i> , 2009 , 35 Suppl 1, 1-22 | 3.6 | 129 |
| 197 | Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. 2009 , 11, R85 | | 21 |
| 196 | PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture. 2009 , 11, R29 | | 12 |
| 195 | Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ. 2009 , 20, 86-87 | | |
| 194 | The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. 2010 , 251, 583-91 | | 37 |

| 193 | Perspectives on margins in DCIS: pathology. 2010 , 8, 1219-22 | 2 |
|-----|---|-----|
| 192 | Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 393-402 | |
| 191 | Advances in local-regional treatment for patients with early-stage breast cancer: a review of the field. 2010 , 10, 180-7 | 8 |
| 190 | Cancer of the Breast. 2010 , 1215-1323 | |
| 189 | Principles of radiation oncology in older adults. 63-86 | |
| 188 | The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. 2010 , 2010, 130-3 | 18 |
| 187 | Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. 2010 , 102, 627-37 | 258 |
| 186 | The impact of adding radiation treatment after breast conservation surgery for ductal carcinoma in situ of the breast. 2010 , 2010, 187-92 | 20 |
| 185 | Communication between patients and providers and informed decision making. 2010 , 2010, 204-9 | 18 |
| 184 | Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective. 2010 , 2010, 178-80 | 10 |
| 183 | Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. 2010 , 102, 170-8 | 421 |
| 182 | Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. 2010 , 2010, 121-9 | 45 |
| 181 | [Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases]. 2010 , 97, 301-10 | 8 |
| 180 | The impact of systemic therapy following ductal carcinoma in situ. 2010 , 2010, 200-3 | 14 |
| 179 | Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. 2010 , 2010, 158-61 | 22 |
| 178 | CD24, a promising biomarker in NSCLC. 2010 , 4, 495 | 3 |
| 177 | Randomized clinical trials in breast cancer. Surgical Oncology Clinics of North America, 2010 , 19, 33-58 2.7 | 6 |
| 176 | Relationship Between Clinical and Pathologic Features of Ductal Carcinoma In Situ and Patient Age: An Analysis of 657 Patients. 2010 , 21, 241-243 | |

| 175 | Handbook of Evidence-Based Radiation Oncology. 2010 , | | 32 |
|-----|--|-----|-----|
| 174 | The impact of publication of Australian treatment recommendations for DCIS on clinical practice: A population-based, "before-after" study. <i>European Journal of Surgical Oncology</i> , 2010 , 36, 949-56 | 3.6 | 3 |
| 173 | Future medical applications of single-cell sequencing in cancer. 2011 , 3, 31 | | 155 |
| 172 | A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial: Pinder SE, on behalf of the UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma In Situ (DCIS) Working Party (King's College London, | | |
| 171 | Early stage breast cancer and radiotherapy: update. 2011 , 57, 459-464 | | |
| 170 | Treatment of ductal carcinoma in situ. 2011 , 343, d5344 | | O |
| 169 | Effect of Radiotherapy Boost and Hypofractionation on Outcomes in Ductal Carcinoma In Situ. 2011 , 22, 278-279 | | |
| 168 | Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. 2011 , 11, 100-7 | | 51 |
| 167 | William Hunter Harridge Lecture: Contemporary management of pre-invasive and early breast cancer. 2011 , 201, 279-89 | | 3 |
| 166 | The role of surgery in metastatic breast cancer. 2011 , 47 Suppl 3, S6-22 | | 56 |
| 165 | Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. 2011 , 12, 21-9 | | 371 |
| 164 | Ductal carcinoma in situ: detection, diagnosis, and characterization with magnetic resonance imaging. 2011 , 32, 306-18 | | 19 |
| 163 | Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. 2011 , 100, 195-9 | | 25 |
| 162 | Accelerated partial breast irradiation for pure ductal carcinoma in situ. 2011 , 81, 403-8 | | 28 |
| 161 | Rates of second malignancies after definitive local treatment for ductal carcinoma in situ of the breast. 2011 , 81, 1244-51 | | 8 |
| 160 | Ipsilateral breast tumor recurrence after breast-conserving surgery for ductal carcinoma in situ. 2011 , 253, 1233; author reply 1233-4 | | |
| 159 | Maximal Sterile Barrier Precautions do Not Reduce Catheter-Related Bloodstream Infections in General Surgery Units. 2011 , 253, 1235 | | |
| 158 | Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma in Situ. 2011 , 253, 1233-1234 | | |

157 Comment On. **2011**, 253, 1236

| 156 | Maximal sterile barrier precautions do not reduce catheter-related bloodstream infections in general surgery units. 2011 , 253, 1234-5; author reply 1235 | | |
|-----------------|--|-----|-----|
| 155 | Effect of Radiotherapy Boost and Hypofractionation on Outcomes in Ductal Carcinoma In Situ. 2011 , 2011, 52-54 | | |
| ¹ 54 | Ductal carcinoma in-situ: an update for clinical practice. 2011 , 20, e23-31 | | 15 |
| 153 | The effect of age in the outcome and treatment of older women with ductal carcinoma in situ. <i>Breast</i> , 2011 , 20, 71-7 | 3.6 | 9 |
| 152 | Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. <i>Annals of Surgical Oncology</i> , 2011 , 18, 119-24 | 3.1 | 24 |
| 151 | Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patients. <i>Annals of Surgical Oncology</i> , 2011 , 18, 1372-9 | 3.1 | 34 |
| 150 | Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2873-8 | 3.1 | 31 |
| 149 | Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 1-14 | 4.4 | 113 |
| 148 | Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Research and Treatment, 2011, 129, 929-38 | 4.4 | 39 |
| 147 | True local recurrences do not metastasize. 2011 , 30, 161-76 | | 9 |
| 146 | Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ. 2011 , 117, 54-62 | | 41 |
| 145 | Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?. 2011 , 80, 25-30 | | 37 |
| 144 | Einfluss der prognostischen Faktoren auf die Therapie des duktalen Carcinoma in situ der Brust. 2011 , 71, 967-972 | | 1 |
| 143 | Structural estimates of treatment effects on outcomes using retrospective data: an application to ductal carcinoma in situ. 2011 , 68, 627-49 | | 2 |
| 142 | Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. 2011 , 103, 478-88 | | 515 |
| 141 | Breast Cancer: Intact and Post Mastectomy. 2011 , 641-684 | | |
| 140 | Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer. 2011 , 2011, 673790 | | 9 |

| 139 | Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons. 2011 , 103, 92-104 | 31 |
|---------------------------------|---|-----------------------|
| 138 | Breast cancer spatial heterogeneity in near-infrared spectra and the prediction of neoadjuvant chemotherapy response. 2011 , 16, 097007 | 11 |
| 137 | Use of tamoxifen before and during pregnancy. 2011 , 16, 1547-51 | 98 |
| 136 | Random physician effect and comparative effectiveness of treatment for ductal carcinoma in situ. 2011 , 103, 81-2 | 2 |
| 135 | The role of preoperative bilateral breast magnetic resonance imaging in patient selection for partial breast irradiation in ductal carcinoma in situ. 2012 , 2012, 206342 | 2 |
| 134 | Ductal carcinoma in situ: what can we learn from clinical trials?. 2012 , 2012, 296829 | |
| 133 | Aktuelles aus der S3-Leitlinie [Pr¶entive und postoperative medikamentße Therapie des duktalen Karzinoms in situ. 2012 , 9, 150-151 | |
| 132 | Network meta-analysis of margin threshold for women with ductal carcinoma in situ. 2012 , 104, 507-16 | 96 |
| 131 | Cancer du sein. 2012 , | |
| | | |
| 130 | Ductal carcinoma in situ of the breast. 2012 , 2012, 123549 | 23 |
| 130 | Ductal carcinoma in situ of the breast. 2012 , 2012, 123549 Ductal carcinoma in situ: recent advances and future prospects. 2012 , 2012, 347385 | 23 5 |
| | | |
| 129 | Ductal carcinoma in situ: recent advances and future prospects. 2012 , 2012, 347385 Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. 2012 , | 5 |
| 129 | Ductal carcinoma in situ: recent advances and future prospects. 2012, 2012, 347385 Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. 2012, 2012, 560493 Radiotherapy after conservative surgery in ductal carcinoma in situ of the breast: a review. 2012, | 5 |
| 129 128 127 | Ductal carcinoma in situ: recent advances and future prospects. 2012, 2012, 347385 Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. 2012, 2012, 560493 Radiotherapy after conservative surgery in ductal carcinoma in situ of the breast: a review. 2012, 2012, 635404 Memorial sloan-kettering cancer center: two decades of experience with ductal carcinoma in situ of | 5 3 8 |
| 129 128 127 | Ductal carcinoma in situ: recent advances and future prospects. 2012, 2012, 347385 Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. 2012, 2012, 560493 Radiotherapy after conservative surgery in ductal carcinoma in situ of the breast: a review. 2012, 2012, 635404 Memorial sloan-kettering cancer center: two decades of experience with ductal carcinoma in situ of the breast. 2012, 2012, 723916 | 5 3 8 |
| 129 128 127 126 125 | Ductal carcinoma in situ: recent advances and future prospects. 2012, 2012, 347385 Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. 2012, 2012, 560493 Radiotherapy after conservative surgery in ductal carcinoma in situ of the breast: a review. 2012, 2012, 635404 Memorial sloan-kettering cancer center: two decades of experience with ductal carcinoma in situ of the breast. 2012, 2012, 723916 Role of the radiotherapy boost on local control in ductal carcinoma in situ. 2012, 2012, 748196 Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of | 5 3 8 1 3 |

| 121 | Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. 2012 , 12, 259-63 | | 22 |
|-----|---|-----|----|
| 120 | Ductal carcinoma in situthe influence of the radiotherapy boost on local control. 2012 , 82, e153-8 | | 38 |
| 119 | Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194: Motwani SB, Goyal S, Moran MS, et al (UMDNJ/Robert Wood Johnson Med School, New Brunswick, NJ; Yale Univ School of Medicine, New Haven, CT; et al) Cancer 117:1156-1162, 2011. 2012, 23, 51-52 | | |
| 118 | Breast scintigraphy with breast-specific Etamera in the detection of ductal carcinoma in situ: a correlation with mammography and histologic subtype. 2012 , 53, 1528-33 | | 14 |
| 117 | Characteristics associated with the initiation of radiation therapy after breast-conserving surgery among African American and white women diagnosed with early-stage breast cancer in Maryland, 2000-2006. 2012 , 22, 28-36 | | 12 |
| 116 | Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study. 2012 , 7, 177 | | 11 |
| 115 | Ductal carcinoma in situ, and the influence of the mode of detection, population characteristics, and other risk factors. 2012 , 45-8 | | 1 |
| 114 | Clinical outcomes of ductal carcinoma in situ of the breast treated with partial mastectomy without adjuvant radiotherapy. 2012 , 53, 537-42 | | 1 |
| 113 | Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. 2012 , 118, 6022-30 | | 11 |
| 112 | Behandlung des duktalen Carcinoma in situ. 2012 , 45, 269-275 | | 2 |
| 111 | Ultrasonography- and/or mammography-guided breast conserving surgery for ductal carcinoma in situ of the breast: experience with 87 lesions. 2012 , 19, 131-7 | | 7 |
| 110 | ACR appropriateness criteria([]) ductal carcinoma in situ. 2012 , 18, 8-15 | | 18 |
| 109 | Radiation therapy for ductal carcinoma in situ: a decision analysis. 2012, 118, 603-11 | | 12 |
| 108 | Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current management. 2012 , 105, 212-20 | | 12 |
| 107 | Intraductal therapy of ductal carcinoma in situ: a presurgery study. 2013, 13, 280-6 | | 12 |
| 106 | Selective use of whole breast radiotherapy after breast conserving surgery for invasive breast cancer and DCIS. 2013 , 11, 278-85 | | 2 |
| 105 | Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 465-76 | 4.4 | 56 |
| 104 | Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Research and Treatment, 2013 , 139, 453-60 | 4.4 | 43 |

| 103 | HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. <i>Breast</i> , 2013 , 22, 894-7 | 3.6 | 8 | |
|-----|---|-----|-----|--|
| 102 | Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases. 2013, 17, 196-201 | | 16 | |
| 101 | Role of radiotherapy boost in women with ductal carcinoma in situ: a single-center experience in a series of 389 patients. <i>European Journal of Surgical Oncology</i> , 2013 , 39, 613-8 | 3.6 | 24 | |
| 100 | Effects of menopausal hormonal therapy on occult breast tumors. 2013 , 137, 150-6 | | 22 | |
| 99 | Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI. <i>Annals of Surgical Oncology</i> , 2013 , 20, 1275-81 | 3.1 | 31 | |
| 98 | Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?. 2013 , 105, 1527-33 | | 32 | |
| 97 | Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 145-54 | 4.4 | 22 | |
| 96 | Interdisziplinটe S3-Leitlinie fīldie Diagnostik, Therapie ´und ´Nachsorge des Mammakarzinoms. 2013 , 10, 164-192 | | 18 | |
| 95 | Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. 2013 , 73, 556-583 | | 41 | |
| 94 | A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ. 2013 , 105, 681-3 | | 9 | |
| 93 | Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. 2013 , 105, 774-81 | | 12 | |
| 92 | Is it time to reevaluate definitive therapy in prostate cancer?. 2013 , 105, 683-5 | | 5 | |
| 91 | A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ. 2013 , 2013, 582134 | | 17 | |
| 90 | Regression of ductal carcinoma in situ after treatment with acupuncture. 2013 , 19, 911-5 | | 5 | |
| 89 | Clinical experience using accelerated partial breast irradiation for ductal carcinoma in situ. 2013 , 19, 217-9 | | | |
| 88 | Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. 2013 , 108, 1593-601 | | 29 | |
| 87 | Significance of immunohistochemistry in breast cancer. 2014 , 5, 382-92 | | 101 | |
| 86 | Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. 2014 21 e96-e104 | | 40 | |

| 85 | The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience. 2014 , 110, 45-50 | | 29 |
|----------------------|---|-----|--------------------|
| 84 | Breast conserving therapy for DCISdoes size matter?. 2014 , 110, 75-81 | | 8 |
| 83 | Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ. 2014 , 2, 22 | | 10 |
| 82 | Cost-effectiveness of 3-dimensional conformal radiotherapy and applicator-based brachytherapy in the delivery of accelerated partial breast irradiation. 2014 , 37, 172-6 | | 6 |
| 81 | Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 343-50 | 4.4 | 85 |
| 80 | Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1552-60 | 3.1 | 43 |
| 79 | Recidivas locorregionales del clicer de mama. 2014 , 50, 1-16 | | |
| 78 | Breast Cancer. 2014 , | | 3 |
| 77 | Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. 2014 , 32, 3613-8 | | 126 |
| | | | |
| 76 | Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. 2014 , 33, 2589-600 | | 144 |
| 76 75 | | | 144 |
| | cancer. 2014 , 33, 2589-600 | | |
| 75 | Radiotherapy in DCIS, an underestimated benefit?. 2014 , 112, 1-8 Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be | 3.1 | 26 |
| 75 74 | Radiotherapy in DCIS, an underestimated benefit?. 2014 , 112, 1-8 Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be avoided? Our experience. 2014 , 12 Suppl 2, S47-S49 Characterization and treatment of local recurrence following breast conservation for ductal | 3.1 | 26 |
| 75 74 73 | Radiotherapy in DCIS, an underestimated benefit?. 2014, 112, 1-8 Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be avoided? Our experience. 2014, 12 Suppl 2, S47-S49 Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. <i>Annals of Surgical Oncology</i> , 2014, 21, 3766-73 Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal | | 26 2 3 |
| 75 74 73 72 | Radiotherapy in DCIS, an underestimated benefit?. 2014, 112, 1-8 Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be avoided? Our experience. 2014, 12 Suppl 2, S47-S49 Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. Annals of Surgical Oncology, 2014, 21, 3766-73 Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. Breast, 2014, 23, 63-8 | | 26 2 3 |
| 75 74 73 72 71 | Radiotherapy in DCIS, an underestimated benefit?. 2014, 112, 1-8 Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be avoided? Our experience. 2014, 12 Suppl 2, S47-S49 Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. Annals of Surgical Oncology, 2014, 21, 3766-73 Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. Breast, 2014, 23, 63-8 Personalized therapy for breast cancer. 2014, 86, 62-7 Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive | | 26 2 3 12 |

Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer. 2015, 67 1 Is Wide Excision Alone an Appropriate Therapy for DCIS?. 2015, 3, 1 66 Ductal carcinoma in situ: recent history and areas of controversy. 2015, 21, 21-6 6 65 Nomogram for predicting the risk of locoregional recurrence in patients treated with accelerated 64 9 partial-breast irradiation. 2015, 91, 312-8 Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the 63 43 University of Southern California/Van Nuys (USC/VNPI) prognostic index. 2015, 21, 127-32 Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast 62 12 4.4 cancer. Breast Cancer Research and Treatment, 2015, 153, 173-81 Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans. 61 13 2015, 4, 24 onlineDeCISion.org: a web-based decision aid for DCIS treatment. Breast Cancer Research and 60 4.4 14 Treatment, **2015**, 154, 181-90 A population-based validation study of the DCIS Score predicting recurrence risk in individuals 59 4.4 152 treated by breast-conserving surgery alone. Breast Cancer Research and Treatment, 2015, 152, 389-98 Final results from a multicenter prospective study (JROSG 05-5) on postoperative radiotherapy for 58 patients with ductal carcinoma in situ with an involved surgical margin or close margin widths of 1 mm or less. 2015, 56, 830-4 Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a 57 23 Community Practice: A Nested, Case-Control Study. *Annals of Surgical Oncology*, **2015**, 22 Suppl 3, S502- $8^{3.1}$ Screening mammography-detected ductal carcinoma in situ: mammographic features based on 56 10 breast cancer subtypes. **2015**, 39, 983-6 Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity 55 43 and response to radiotherapy. 2015, 33, 327-41 Breast Ductal Carcinoma: A Literature Review of Adjuvant Hormonal Therapy. 2016, 10, 304 54 Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. 28 53 2016, 25, 19-28 52 The importance of surgical margins in breast cancer. **2016**, 113, 256-63 30 Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United 51 4 States \$35 Million/y. 2016, 40, 1090-9 A Review of Local and Systemic Therapy in Breast Cancer. 2016, 731-764 50

49 Surgical Oncology Manual. 2016,

| 48 | Noninvasive Breast Cancer. 2016 , 1303-1312.e3 | | |
|----|--|------|----|
| 47 | Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. 2016 , 11, 425-432 | | 1 |
| 46 | Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. 2016 , 139, 2127-34 | | 22 |
| 45 | The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3811-3 | 3821 | 94 |
| 44 | Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ. 2016 , 34, 3963-3968 | | 39 |
| 43 | Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 541-9 | 4.4 | 5 |
| 42 | Ductal Carcinoma In Situ. 2016 , 131-143 | | |
| 41 | Breast Disease. 2016 , | | 3 |
| 40 | Current approach and future perspective for ductal carcinoma in situ of the breast. 2017 , 47, 671-677 | | 36 |
| 39 | Breast-Conserving Surgery Alone for Ductal Carcinoma In Situ: Factors Associated with Increased Risk of Local Recurrence. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1221-1226 | 3.1 | 7 |
| 38 | Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. 2017 , 55, 163-172 | | 20 |
| 37 | Impact of hormonal status on outcome of ductal carcinoma in situ treated with breast-conserving surgery plus radiotherapy: Long-term experience from two large-institutional series. <i>Breast</i> , 2017 , 33, 139-144 | 3.6 | 6 |
| 36 | Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic Calal⊞Occit⊞Catalonia survey with 9-year follow up. <i>Breast</i> , 2017 , 35, 196-202 | 3.6 | 4 |
| 35 | Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2017 , 161, 17-28 | 4.4 | 68 |
| 34 | Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2017 , 24, 660-668 | 3.1 | 18 |
| 33 | Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. <i>JAMA Oncology</i> , 2017 , 3, 101-104 | 13.4 | 2 |
| 32 | Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma patients: a network meta-analysis. <i>Oncotarget</i> , 2017 , 8, 79257-79269 | 3.3 | 4 |

| 31 | Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 311-322 | 10 |
|----|---|----|
| 30 | Ductal Carcinoma in Situ of the Breast. 2018 , 562-575.e4 | 3 |
| 29 | Endocrine Therapy for Breast Cancer. 2018 , 907-923.e6 | 2 |
| 28 | Breast Cancer Screening. 2018, 147-156 | 1 |
| 27 | Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 957-962 | 8 |
| 26 | Non-palpable Lesions Localization in DCIS. 2018 , 91-105 | |
| 25 | Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 751-759 | 12 |
| 24 | Precursor Lesions of the Low-Grade Breast Neoplasia Pathway. Surgical Pathology Clinics, 2018, 11, 177-1997 | 10 |
| 23 | Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?. Surgical Oncology Clinics of North America, 2018, 27, 69-80 | 3 |
| 22 | A New Perspective on Breast Cancer Diagnostic Guidelines to Reduce Overdiagnosis. SSRN Electronic Journal, 2018, | O |
| 21 | Breast and Axilla Treatment in Ductal Carcinoma In Situ. 2018, | |
| 20 | Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky063 | 12 |
| 19 | Atypical Breast Proliferative Lesions and Benign Breast Disease. 2018, | |
| 18 | Ductal Carcinoma In Situ. Surgical Clinics of North America, 2018, 98, 725-745 4 | 7 |
| 17 | Updates in the Evaluation and Management of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 794-8076.4 | 28 |
| 16 | Association of Transforming Growth Factor IPolymorphism C-509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer: A Secondary Analysis of a Randomized 13.4 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1751-1757 | 20 |
| 15 | Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study. <i>Breast</i> , 2018 , 42, 10-14 | 4 |
| 14 | Treatment results in patients with ductal carcinoma in situ treated with adjuvant radiotherapy. Turkish Journal of Medical Sciences, 2019 , 49, 1151-1156 | |

A Review of Local and Systemic Therapy in Breast Cancer. **2019**, 637-690

| 12 | How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Current Breast Cancer Reports</i> , 2019 , 11, 175-184 | 0.8 | |
|----|---|-----|----|
| 11 | Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2383-2396 | 4.9 | 10 |
| 10 | Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score. <i>American Journal of Roentgenology</i> , 2019 , 212, 919-924 | 5.4 | 3 |
| 9 | Overexpression of ASPM, CDC20, and TTK Confer a Poorer Prognosis in Breast Cancer Identified by Gene Co-expression Network Analysis. <i>Frontiers in Oncology</i> , 2019 , 9, 310 | 5.3 | 35 |
| 8 | Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions. <i>Current Oncology Reports</i> , 2019 , 21, 33 | 6.3 | 11 |
| 7 | Breast Disease. 2019 , | | |
| 6 | External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial. <i>Tumori</i> , 2019 , 105, 205-209 | 1.7 | 1 |
| 5 | Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis. <i>Pathology and Oncology Research</i> , 2020 , 26, 521-531 | 2.6 | 3 |
| 4 | Weighted gene correlation network analysis identifies RSAD2, HERC5, and CCL8 as prognostic candidates for breast cancer. <i>Journal of Cellular Physiology</i> , 2020 , 235, 394-407 | 7 | 21 |
| 3 | Breast Cancer. 2020 , 49-100 | | |
| 2 | Pros and cons of radiotherapy omission in elderly breast cancer patients following breast conservative surgery <i>Translational Cancer Research</i> , 2020 , 9, S236-S241 | 0.3 | Ο |
| 1 | Evolving Trends in Surgical Management of Breast Cancer: An Analysis of 30 Years of Practice Changing Papers. <i>Frontiers in Oncology</i> , 2021 , 11, 622621 | 5.3 | О |